This Article Full Text Full Text (PDF) All Versions of this Article: 42/5/1034    most recent 01.HYP.0000097604.64716.D2v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nishikimi, T. Articles by Matsuoka, H. Search for Related Content PubMed PubMed Citation Articles by Nishikimi, T. Articles by Matsuoka, H. Related Collections Heart failure - basic studies

(Hypertension. 2003;42:1034.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Chronic Administration of Adrenomedullin Attenuates Transition From Left Ventricular Hypertrophy to Heart Failure in Rats

Toshio Nishikimi; Fumiki Yoshihara; Shigeo Horinaka; Naohiko Kobayashi; Yosuke Mori; Kazuyoshi Tadokoro; Kazumi Akimoto; Naoto Minamino; Kenji Kangawa; Hiroaki Matsuoka

From the Department of Hypertension and Cardiorenal Medicine (T.N., S.H., N.K., Y.M., K.T., H.M.) and the Laboratory of Molecular and Cellular Biology (K.A.), Dokkyo University School of Medicine, Tochigi, Japan; and the Research Institute (F.Y., N.M., K.K.), National Cardiovascular Center, Osaka, Japan.

Correspondence to Toshio Nishikimi, MD, Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi 321-0293, Japan. E-mail nishikim{at}dokkyomed.ac.jp

Acute administration of adrenomedullin (AM) exerts beneficial hemodynamic, renal, and neurohormonal effects in heart failure (HF). However, chronic effects of AM administration on HF remain unknown. This study sought to examine the effect of chronic infusion of AM on progression of HF in rat. Human recombinant AM was administered by osmotic minipump for 7 weeks in the HF model of Dahl salt-sensitive rats. The effect was compared with vehicle and diuretic treatment group. Chronic AM infusion significantly decreased left ventricular end-diastolic pressure, right ventricular systolic pressure, right atrial pressure, and left ventricular weight/body weight (P<0.01 for all). AM significantly attenuated the increase in circulating renin-aldosterone, endogenous rat AM, and atrial natriuretic peptide levels (P<0.01 for all). AM also inhibited the myocardial tissue levels of angiotensin II and atrial and brain natriuretic peptide (P<0.01 for all). These changes were associated with the improvement of cardiac output and systemic vascular resistance (both P<0.05). Furthermore, AM improved left ventricular end-systolic elastance (P<0.01). These improvements were greater in the AM than in the diuretic group, although both drugs similarly decreased systolic blood pressure and increased urinary sodium excretion. Kaplan-Meier survival analysis showed that AM significantly prolonged survival time compared with diuretic (P<0.05) and vehicle (P<0.01) treatment groups. These results suggest that endogenous AM plays a compensatory role in HF and that chronic AM infusion attenuates progression of left ventricular dysfunction and improves survival, at least in part, through inhibition of circulating and myocardial neurohormonal activation.

Key Words: adrenomedullin • heart failure • renin • natriuretic peptides • angiotensin

This article has been cited by other articles:

				C. Adlbrecht, M. Hulsmann, G. Strunk, R. Berger, D. Mortl, J. Struck, N. G. Morgenthaler, A. Bergmann, J. Jakowitsch, G. Maurer, et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients Eur J Heart Fail, April 1, 2009; 11(4): 361 - 366. [Abstract] [Full Text] [PDF]

				N. Nagaya, K. Kangawa, T. Itoh, T. Iwase, S. Murakami, Y. Miyahara, T. Fujii, M. Uematsu, H. Ohgushi, M. Yamagishi, et al. Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy Circulation, August 23, 2005; 112(8): 1128 - 1135. [Abstract] [Full Text] [PDF]

				N. Nagaya, H. Mori, S. Murakami, K. Kangawa, and S. Kitamura Adrenomedullin: angiogenesis and gene therapy Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1432 - R1437. [Abstract] [Full Text] [PDF]

				T. Nishikimi, K. Tadokoro, K. Akimoto, Y. Mori, Y. Ishikawa, K. Ishimura, T. Horio, K. Kangawa, and H. Matsuoka Response of adrenomedullin system to cytokine in cardiac fibroblasts-role of adrenomedullin as an antifibrotic factor Cardiovasc Res, April 1, 2005; 66(1): 104 - 113. [Abstract] [Full Text] [PDF]

				K.-D. Schluter and K. C Wollert Synchronization and integration of multiple hypertrophic pathways in the heart Cardiovasc Res, August 15, 2004; 63(3): 367 - 372. [Full Text] [PDF]